Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zura Bio Limited - Class A Ordinary shares (NQ:ZURA)

6.250 +0.240 (+3.99%)
Streaming Delayed Price Updated: 1:13 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zura Bio Limited - Class A Ordinary shares

< Previous 1 2 Next >
News headline image
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Business Updates and Outlook for 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zura Bio
Via Business Wire
News headline image
Zura Bio Announces Chief Financial Officer Transition
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Present at the Jefferies Global Healthcare Conference
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Participate in Two Upcoming Investor Conferences in November
From Zura Bio
Via Business Wire
News headline image
Zura Bio to Present at Three Upcoming Investor Conferences in September
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants
From Zura Bio Limited
Via Business Wire
News headline image
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Announces Participation in June Investor Conferences
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
From Zura Bio
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.